Via: Business Wire
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that it raised $132 million in a Series D equity financing. The round was led by new investor Mubadala Investment Company, Abu Dhabi’s leading investment company, active in numerous sectors and more than 30 countries around the world. Existing investors Baxter Ventures, the venture capital arm of Baxter International, Fidelity Management and Research Company, Partner Fund Management LP, Perceptive Advisors, funds advised by T. Rowe Price Associates Inc., and Warburg Pincus also participated in the equity round.
The company will use the proceeds from the financing to increase production capabilities and accelerate commercial expansion of its Tablo®Hemodialysis System in acute and chronic care markets in the United States. Designed to reduce the cost and complexity of dialysis, Tablo expands how, when, and where dialysis can be provided.
Read More: https://www.businesswire.com/news/home/20180828005589/en/Outset-Medical-Closes-132-Million-Financing-Accelerate
RSS Feed
